- Kriya given field-based exclusivity for use of Everads’ platform using gene therapy against certain prespecified therapeutic targets
- Agreement follows a year-long collaboration between the Parties evaluating Everads’ technology for delivery of gene therapy
- Recent publication in TVST highlights the safety and rapid distribution throughout the posterior pole in non-human primates achieved with Everads’ technology
Everads Therapy, an ophthalmology-focused biotechnology company developing a novel platform that enables non-surgical office-based delivery of therapy to the back of the eye via the suprachoroidal space, announced today that it has entered into a license, collaboration and supply agreement with Kriya Therapeutics, Inc. (“Kriya”) to advance Kriya’s portfolio of gene therapies for retinal diseases using Everads’ suprachoroidal delivery platform. The agreement follows a research collaboration between the parties whereby Everads’ platform was evaluated for delivery of the company’s gene therapy candidates in non-human primate models.
Under the terms of the agreement, Kriya was granted field-based exclusivity for use of Everads’ platform using gene therapy against certain prespecified therapeutic targets including ophthalmic diseases that involve the complement cascade, while Everads retains the right to continue using and/or licensing its technology to other parties for the development of other therapeutic targets using gene therapy, as well as all non-gene therapy applications. Everads received an undisclosed upfront payment and is entitled to receive development milestones and royalties on net sales of products using Everads’ platform.
“Recent data has shown the promise that the suprachoroidal route of administration has for providing a safe and targeted approach for gene therapy,” said Moshe Weinstein, Everads’ Executive Chairman and CEO. “We are extremely excited to enter into this license agreement after a thorough evaluation of our technology and its applicability for delivery of gene therapy. This agreement is a further validation of the uniqueness of our suprachoroidal delivery technology.”
The suprachoroidal space, which is an emerging route of administration for therapies targeting the back of the eye, is the space between the sclera and choroid that circumferentially spans the entire posterior segment of the eye. An increasing number of preclinical and clinical investigations in treating retinal diseases, including via gene therapy, have demonstrated the promise of this route of administration.
Everads believes that its suprachoroidal delivery system will enable safe and effective in-office delivery of therapy to target choroidal and retinal tissues via the suprachoroidal space and is differentiated by its ability to deliver therapy rapidly throughout the posterior pole. The ability of Everads’ technology to enable rapid distribution to the macular region in non-human primate models was the focus of a recent publication in Translational Vision Science and Technology (TVST).
About Everads Therapy
Everads Therapy is a biotech company focused on optimizing treatment of retinal diseases using its proprietary suprachoroidal delivery technology. With the aim of overcoming challenges in current treatment methodologies for retinal and macular diseases, Everads’ delivery platform offers the promise of improving the efficacy and safety of existing and potential drug therapies via suprachoroidal delivery. Everads has a number of collaborations in the areas of gene therapy, cell therapy, small molecule formulations and other modalities. Everads was spun out of DALI Medical Devices, a company specializing in development of injectable drug delivery technologies, and established within RAD Biomed, a leading biotech incubator in Israel. Everads’ underlying technologies were licensed from the Sheba Tel Hashomer Medical Center / Sheba Impact.
About Kriya Therapeutics
Kriya’s mission is to revolutionize medicine, with the ultimate goal of eliminating human suffering and enabling people to live without the burden of disease. Kriya is a biopharmaceutical company developing gene therapies to address diseases affecting millions of people around the world. With operations in Palo Alto, California and Research Triangle Park, North Carolina, Kriya has raised over $600 million in committed capital, which will be used to advance a broad pipeline of gene therapies for ophthalmology, neurology and metabolic disease.
Check out our AAV CDMO service to expedite your gene therapy research
PackGene is a CRO & CDMO technology company that specializes in packaging recombinant adeno-associated virus (rAAV) vectors. Since its establishment in 2014, PackGene has been a leader in the AAV vector CRO service field, providing tens of thousands of custom batches of AAV samples to customers in over 20 countries. PackGene offers a one-stop CMC solution for the early development, pre-clinical development, clinical trials, and drug approval of rAAV vector drugs for cell and gene therapy (CGT) companies that is fast, cost-effective, high-quality, and scalable. Additionally, the company provides compliant services for the GMP-scale production of AAVs and plasmids for pharmaceutical companies, utilizing five technology platforms, including the π-Alpha™ 293 cell AAV high-yield platform and the π-Omega™ plasmid high-yield platform. PackGene’s mission is to make gene therapy affordable and accelerate the launch of innovative gene drugs. The company aims to simplify the challenging aspects of gene therapy development and industrialization processes and provide stable, efficient, and economical rAAV Fast Services to accelerate gene and cell therapy development efforts from discovery phase to commercialization.
Another Two-Plasmid AAV Gene Therapy Enters Clinical Trial: Gene Vector Biotechnology’s JWK001 Pioneers in Treating nAMD
On November 30, 2023, Gene Vector Biotechnology Co., Ltd. in Chengdu, China, received approval from the National Medical Products Administration's Center for Drug Evaluation (CDE) for the clinical trial of JWK001, a Class I gene therapy drug for treating neovascular...
Accelerating Gene Therapy Production: Combining next-generation AAV vectors and artificial intelligence (AI)
Recently, the France-based WIDGeT consortium emerged from a collaboration between Sanofi, WhiteLab Genomics, the TaRGeT Laboratory at Nantes University, and Institut Imagine. Scientists and companies in this consortium hope to speed up the development of gene...
First patient received dose level 2 of RGX-202, a potential one-time AAV Therapeutic for the treatment of Duchenne that includes an optimized transgene for a novel microdystrophin On track for pivotal dose determination and initiation of pivotal program in 2024...
Hodgkin lymphoma, nodular lymphocyte predominant (high-power view) Credit: Gabriel Caponetti, MD./Wikipedia/CC BY-SA 3.0The University of Pennsylvania plans to continue offering CAR-T therapy, a cancer treatment pioneered at Penn, after the Food and Drug...
Plasmids GMP Services
Multiple scales & grade of solutions of various kind of plasmids suitable for multiple treatments in a fast and cost effective way.
AAV GMP Services
Ranging from small-scale AAV production, to large-scale AAV cGMP manufacturing for animal studies.
PackGene’s proprietary π-Alpha™ 293 AAV High-yield Platform increases AAV production by 3 to 8 times that of traditional platforms.